Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery
NCT00226369
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
242
Enrollment
OTHER
Sponsor class
Conditions
Congenital Heart Defects
Interventions
DRUG:
CY-1503
Sponsor
Boston Children's Hospital